查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086105

骨髓發育不良症候群市場：2026-2032年全球市場預測（按產品類型、治療線、療法、給藥途徑、最終用戶和分銷管道分類）

Myelodysplastic Syndrome Market by Product Type, Therapy Line, Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨髓發育不良症候群市場將成長至 52.3 億美元，複合年成長率為 8.42%。

主要市場統計數據
基準年 2025 29.7億美元
預計年份：2026年 32.1億美元
預測年份 2032 52.3億美元
複合年成長率 (%) 8.42%

骨髓發育不良症候群（通常縮寫為MDS）是一組克隆性造血幹細胞疾病，其特徵為血球生成受損、持續性血球減少、骨髓增生異常以及進展為急性骨髓性白血病的風險不一。此病的發生率集中於老年人群，基於人群的研究通常報告其發生率約為每年每10萬人4例，且70歲以上人群的發生率顯著更高。

由於分子分型準確性的提高、貧血治療方案的擴展以及次世代定序在常規血液學實踐中的廣泛應用，骨髓發育不良症候群(MDS) 的市場正在發生變化。目前，臨床決策主要基於 IPSS-R 和 IPSS-M 等綜合風險模型，這些模型反映了分子資訊。然而，治療選擇仍有分歧：低風險 MDS 的治療目標是實現輸血獨立，而高風險 MDS 的治療目標是提高存活率、預防急性骨髓性白血病(AML) 以及確保患者俱備移植合格。

MDS治療前景的變革性變化

骨髓增生異常綜合症（MDS）的治療格局正從基於形態學的診斷轉向包含基因組學、細胞遺傳學和臨床風險評估的綜合方法。 2022年世界衛生組織和國際共識分類的修訂版重申了SF3B1突變和TP53雙等位基因惰性等遺傳異常在確定疾病分類和預後方面的重要性。這導致對分子診斷、微小殘留疾病（MRD）檢測和專業血液病理服務的需求增加。

人工智慧在MDS中的累積影響

人工智慧 (AI) 透過改進複雜資料集的解讀，正在對骨髓增生異常綜合症 (MDS) 的發現、診斷和醫療服務的各個階段產生累積影響。 AI 驅動的影像分析有助於評估骨髓形態，而應用於基因組學、細胞遺傳學、實驗室觀察和臨床變量的機器學習模型，在經過不同隊列的檢驗後，有望實現超越傳統評分的更優風險分層。

關於骨髓發育不良症候群的關鍵區域性見解

北美在先進MDS診斷和新型療法的應用方面處於領先地位，這得益於其密集的血液學網路、積極應用次世代定序、參與臨床試驗的機會以及完善的癌症治療創新報銷機制。在歐洲，儘管臨床指引的一致性、血液病理學專業知識和臨床試驗參與度都很高，但不同國家醫療技術評估系統和醫院採購模式的差異導致醫療資源取得情況有所不同。亞太地區正在快速發展，日本、中國、韓國、澳洲和印度正在加強其血液學基礎設施、基因組檢測能力、登記系統以及專科癌症療法的取得。

關於骨髓發育不良症候群的關鍵小組見解

在東協地區，新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國透過加強三級醫療機構建設，正在擴大MDS（骨髓增生異常症候群）的醫療基礎設施，但獲得次世代定序、專業血液病理學、新的醫保覆蓋療法和移植的機會仍然不穩定。在海灣合作理事會（GCC）國家，沙烏地阿拉伯、阿拉伯聯合大公國、卡達、科威特、巴林和阿曼正透過投資公共衛生和發展專業醫療中心，建構先進的血液學基礎設施，為低危險群和高風險MDS患者的分子診斷、最佳化輸血和創新療法創造機會。

主要國家骨髓發育不良症候群症候群的趨勢

美國仍然是骨髓增生異常症候群（MDS）治療領域的創新中心，這得益於FDA批准的療法、基於指南的治療、老年人醫療保險覆蓋、廣泛的分子檢測以及大量的臨床試驗活動。在加拿大，重點在於基於實證醫學的保險報銷和血液科醫生的診療服務。與此同時，墨西哥和巴西正在擴大其診斷、輸血支持和腫瘤治療基礎設施，儘管存在區域差異。在歐洲，英國、德國、法國、義大利和西班牙在血液學領域保持著高水準的專業技術、完善的治療路徑，並積極參與臨床研究。另一方面，俄羅斯擁有完善的專科醫療體系，但醫療服務的可近性取決於採購、地區政策以及先進診斷技術的普及程度。

為MDS產業領導者提供的實用建議

產業領導者應優先考慮產生能夠反映實際MDS治療決策的證據，包括輸血獨立性、血液學改善、轉化為急性骨髓性白血病（AML）、總生存期、不利事件負擔、鐵過載、住院利用率以及患者自述疲勞。在商業策略中，MDS不應被視為單一市場，而應細分為低風險MDS、高風險MDS、del(5q)型、SF3B1變異型、TP53變異型、環狀鐵粒幼細胞陽性以及合格移植的患者群體。

調查方法

本次高階主管評估基於已通過核准的治療適應症、血液學指南、同行評審證據、公共衛生資訊來源以及公開的醫療保健市場進入信息。檢驗調查方法著重於臨床試驗終點、真實世界治療模式、診斷應用、監管環境和區域醫療保健服務能力進行交叉檢驗。

結論

隨著分子分型、針對貧血的創新療法、低甲基化療法、支持性治療和移植途徑的融合，骨髓發育不良症候群(MDS) 市場正進入一個更複雜且競爭激烈的階段。人口老化、血球減少症檢測能力的提高以及次世代定序的普及，正在推動診斷間隔時間的延長，並增加對個人化治療的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章骨髓發育不良症候群市場：依產品類型分類

  • 品牌
  • 非專利的

第8章骨髓發育不良症候群市場：依治療線分類

  • 第 1 行
  • 第二行
  • 第三行

第9章骨髓發育不良症候群市場：依治療方法分類

  • 化療藥物
    • Cytarabine
    • 道諾黴素
  • 低甲基化劑
    • Azacitidine
    • Decitabine
    • 癒創甘油醚
  • 免疫調節劑
    • Lenalidomide
    • Pomalidomide
    • Thalidomide
  • 支持性護理
    • 輸血
    • 生長因子
  • 標靶治療
    • IDH抑制劑
    • 魯斯帕特塞普
    • 維內托克拉克斯

第10章骨髓發育不良症候群市場：依給藥途徑分類

  • 口服
  • 皮下
  • 靜脈

第11章骨髓發育不良症候群市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章骨髓發育不良症候群市場：依通路分類

  • 離線
  • 線上

第13章骨髓發育不良症候群市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章骨髓發育不良症候群市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章骨髓發育不良症候群市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celator Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Jazz Pharmaceuticals plc
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Novimmune SA
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3A8C0

The Myelodysplastic Syndrome Market is projected to grow by USD 5.23 billion at a CAGR of 8.42% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.97 billion
Estimated Year [2026] USD 3.21 billion
Forecast Year [2032] USD 5.23 billion
CAGR (%) 8.42%

Myelodysplastic syndrome, commonly abbreviated as MDS, is a group of clonal hematopoietic stem cell disorders characterized by ineffective blood cell production, persistent cytopenias, bone marrow dysplasia, and variable risk of progression to acute myeloid leukemia. The disease burden is concentrated in older adults, with population-based studies commonly reporting incidence near 4 cases per 100,000 people annually and substantially higher rates among people over age 70.

The myelodysplastic syndrome market is being reshaped by better molecular classification, expanded anemia treatment options, and increasing use of next-generation sequencing in routine hematology care. Clinical decision-making now relies on integrated risk models, including IPSS-R and the molecularly informed IPSS-M, while treatment selection continues to split between lower-risk MDS focused on transfusion independence and higher-risk MDS focused on survival, AML prevention, and transplant eligibility.

Transformative Shifts in the MDS Treatment Landscape

The MDS landscape is shifting from morphology-led diagnosis toward integrated genomic, cytogenetic, and clinical risk assessment. The 2022 WHO and International Consensus Classification updates reinforced the importance of genetic lesions, such as SF3B1 mutation and biallelic TP53 inactivation, in defining disease entities and prognosis. This is increasing demand for molecular diagnostics, measurable residual disease research, and specialized hematopathology services.

Therapeutic change is also accelerating. Established options such as erythropoiesis-stimulating agents, lenalidomide for del(5q) lower-risk MDS, hypomethylating agents, and allogeneic hematopoietic stem cell transplantation are now complemented by newer anemia-directed therapies, including luspatercept and imetelstat for selected lower-risk transfusion-dependent patients. These shifts are expanding opportunities across supportive care, targeted hematology, transplant pathways, and real-world evidence generation.

Cumulative Impact of Artificial Intelligence in MDS

Artificial intelligence is having a cumulative impact across MDS discovery, diagnosis, and care delivery by improving the interpretation of complex datasets. AI-enabled image analysis can support bone marrow morphology review, while machine learning models applied to genomic, cytogenetic, laboratory, and clinical variables may improve risk stratification beyond conventional scoring when validated in diverse cohorts.

The most immediate value is operational and clinical: faster identification of trial-eligible patients, automated extraction of transfusion dependence from electronic health records, prediction of treatment response, and pharmacovigilance using real-world data. For industry leaders, AI will be most credible when combined with transparent model governance, bias testing across age and ancestry groups, and clinical validation against endpoints such as overall survival, AML transformation, transfusion independence, and quality of life.

Key Regional Insights for Myelodysplastic Syndrome

North America leads adoption of advanced MDS diagnostics and novel therapies, supported by dense hematology networks, high use of next-generation sequencing, clinical trial access, and established reimbursement pathways for oncology innovation. Europe shows strong clinical guideline alignment, hematopathology expertise, and trial participation, although access varies across national health technology assessment systems and hospital procurement models. Asia-Pacific is expanding rapidly as Japan, China, South Korea, Australia, and India strengthen hematology infrastructure, genomic testing capacity, registries, and access to specialty oncology medicines.

Latin America demonstrates rising diagnosis and treatment demand, led by Brazil and Mexico, but faces uneven access to molecular testing, transfusion services, hypomethylating agents, and transplant centers. The Middle East is investing in tertiary cancer centers, particularly in GCC countries, with growing reliance on specialist hematology, genomic medicine, and cross-border referral models. Africa remains constrained by late diagnosis, limited hematopathology capacity, variable blood product availability, and low access to allogeneic transplantation. Across all regions, aging populations, improved recognition of unexplained cytopenias, and broader use of bone marrow and molecular workups are increasing the diagnosed MDS patient pool.

Key Group Insights for Myelodysplastic Syndrome

Within ASEAN, MDS care is expanding through stronger tertiary hospitals in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, but access to next-generation sequencing, specialist hematopathology, reimbursed novel therapies, and transplant remains uneven. The GCC is building advanced hematology capacity through public health investment and specialist medical centers in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, creating opportunities for molecular diagnostics, transfusion optimization, and innovative therapies for lower-risk and higher-risk MDS.

The European Union benefits from centralized regulatory science, multinational clinical trials, structured pharmacovigilance, and robust hematology societies, while BRICS countries present a high-volume opportunity shaped by China and India's large aging populations, Brazil's oncology infrastructure, Russia's specialist networks, and South Africa's regional referral role. G7 countries drive much of the high-value innovation through research funding, regulatory approvals, guideline adoption, and payer evaluation frameworks. NATO members overlap significantly with advanced Western healthcare markets, reinforcing supply-chain resilience, collaborative clinical research, and preparedness for critical medicines and blood product continuity in hematology care.

Key Country Insights for Myelodysplastic Syndrome

The United States remains the largest innovation hub for MDS treatment, supported by FDA-approved therapies, guideline-driven care, Medicare coverage for older adults, molecular testing uptake, and broad clinical trial activity. Canada emphasizes evidence-based reimbursement and specialist hematology access, while Mexico and Brazil are expanding diagnosis, transfusion support, and oncology infrastructure despite regional disparities. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong hematology expertise, established treatment pathways, and active participation in clinical research, while Russia has significant specialist capacity with access shaped by procurement, regional policy, and availability of advanced diagnostics.

China is scaling oncology infrastructure, genomic testing, and domestic clinical research quickly, while India offers large unmet need with growing private and public hematology capacity and variable access to bone marrow diagnostics, blood products, and transplant services. Japan has a mature, aging-population-driven MDS care model with strong clinical research and high awareness of cytopenias in older adults. Australia provides high-quality hematology care through centralized referral systems and evidence-based reimbursement processes, while South Korea combines advanced diagnostics, strong biomedical research activity, and high digital health adoption. Country-level success depends on early diagnosis, transfusion access, molecular testing, specialist referral, and reimbursement for newer anemia-directed and disease-modifying therapies.

Actionable Recommendations for MDS Industry Leaders

Industry leaders should prioritize evidence generation that reflects real MDS treatment decisions, including transfusion independence, hematologic improvement, AML transformation, overall survival, adverse event burden, iron overload, hospital utilization, and patient-reported fatigue. Commercial strategies should segment lower-risk MDS, higher-risk MDS, del(5q) disease, SF3B1-mutated disease, TP53-altered disease, ring sideroblast-positive disease, and transplant-eligible populations rather than treating MDS as a single market.

Organizations should invest in companion-ready diagnostics, real-world data partnerships, clinical trial diversity, and payer evidence demonstrating reduced transfusion burden and hospital utilization. Success will increasingly depend on integrated offerings that connect molecular testing, therapy selection, response monitoring, adverse event management, and long-term patient support in both academic and community hematology settings.

Research Methodology

This executive assessment is built from verified clinical, regulatory, epidemiological, and market-access inputs, including disease classification standards, approved therapy labels, hematology guidelines, peer-reviewed evidence, public health sources, and publicly available health system information. The methodology emphasizes triangulation across clinical trial endpoints, real-world treatment patterns, diagnostic adoption, regulatory status, and regional healthcare capacity.

Insights are organized to support strategic decision-making in the myelodysplastic syndrome market without using market sizing, market share, or forecasting assumptions. Findings were evaluated through therapeutic area segmentation, regional access mapping, technology impact assessment, and policy review, with particular attention to lower-risk and higher-risk MDS, transfusion dependence, genomic testing adoption, transplant pathways, and the role of AI-enabled evidence generation.

Conclusion

The myelodysplastic syndrome market is entering a more precise and competitive phase as molecular classification, anemia-directed innovation, hypomethylating strategies, supportive care, and transplant pathways converge. Aging populations, improved cytopenia workups, and broader next-generation sequencing access are increasing diagnosed prevalence and sharpening demand for tailored treatments.

The strongest opportunities will emerge for organizations that combine clinically meaningful therapies with validated diagnostics, payer-relevant outcomes, real-world evidence, and region-specific access strategies. As AI, genomic medicine, and data-driven hematology mature, MDS care is expected to become more personalized, measurable, and outcome-driven across global hematology markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Myelodysplastic Syndrome Market, by Product Type

  • 7.1. Branded
  • 7.2. Generic

8. Myelodysplastic Syndrome Market, by Therapy Line

  • 8.1. First Line
  • 8.2. Second Line
  • 8.3. Third Line

9. Myelodysplastic Syndrome Market, by Treatment Type

  • 9.1. Chemotherapy Agents
    • 9.1.1. Cytarabine
    • 9.1.2. Daunorubicin
  • 9.2. Hypomethylating Agents
    • 9.2.1. Azacitidine
    • 9.2.2. Decitabine
    • 9.2.3. Guadecitabine
  • 9.3. Immunomodulators
    • 9.3.1. Lenalidomide
    • 9.3.2. Pomalidomide
    • 9.3.3. Thalidomide
  • 9.4. Supportive Care
    • 9.4.1. Blood Transfusions
    • 9.4.2. Growth Factors
  • 9.5. Targeted Therapies
    • 9.5.1. IDH Inhibitors
    • 9.5.2. Luspatercept
    • 9.5.3. Venetoclax

10. Myelodysplastic Syndrome Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Subcutaneous
  • 10.3. Intravenous

11. Myelodysplastic Syndrome Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Myelodysplastic Syndrome Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Myelodysplastic Syndrome Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Myelodysplastic Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Myelodysplastic Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Arrowhead Pharmaceuticals, Inc.
  • 17.4. Astellas Pharma Inc.
  • 17.5. AstraZeneca plc
  • 17.6. Bristol-Myers Squibb Company
  • 17.7. Celator Pharmaceuticals, Inc.
  • 17.8. Eli Lilly and Company
  • 17.9. Gilead Sciences, Inc.
  • 17.10. GlaxoSmithKline plc
  • 17.11. Incyte Corporation
  • 17.12. Jazz Pharmaceuticals plc
  • 17.13. Merck & Co., Inc.
  • 17.14. MorphoSys AG
  • 17.15. Novartis AG
  • 17.16. Novimmune SA
  • 17.17. Pfizer Inc.
  • 17.18. Roche Holding AG
  • 17.19. Sanofi S.A.
  • 17.20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTARABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYTARABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTARABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DAUNORUBICIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DAUNORUBICIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DAUNORUBICIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AZACITIDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AZACITIDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AZACITIDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DECITABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DECITABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GUADECITABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GUADECITABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GUADECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LENALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LENALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LENALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POMALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POMALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POMALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD TRANSFUSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD TRANSFUSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD TRANSFUSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IDH INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IDH INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IDH INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUSPATERCEPT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUSPATERCEPT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUSPATERCEPT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VENETOCLAX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VENETOCLAX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VENETOCLAX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE,